Assertio Holdings, Inc. — Cyborg Score 7/10

Strategic Profile

The company has pivoted from a cost-cutting exercise to a growth-oriented strategy by exiting non-core assets and doubling down on high-margin products. Key products Rolvedon and Sympazan saw sequential sales increases of 20% and 18.5% respectively in Q2 2025.

Cyborg Score Rationale

Trading at a price-to-cash ratio of 0.72 and price-to-EBITDA multiple of 6.5x, ASRT is trading at a discount to historical averages and industry peers. The company has resolved major legal liabilities reducing future legal exposure by over 80% and now has bandwidth to focus on growth rather than defense.

Top Insights

• Company streamlined operations by exiting OTREXUP while doubling down on Rolvedon and Sympazan, which showed strong sequential growth in 2025.
• Market cap of $70 million is dwarfed by $98.2 million cash reserves, indicating significant cash coverage.
• Q3 2025 earnings beat consensus significantly with $1.65 EPS versus -$1.275 consensus estimate.
• Resolved major litigation including Glumetza antitrust cases, eliminating historical legal overhang.

Named Competitors

• Neurology & Pain Products — Large-cap pharma with broad neurology portfolio
• Specialty Pain Management — Specialty pharma focused on pain management
• Rare Disease & Specialty — Small-cap specialty pharma competitor

Recent Developments

• (November 2025) Filed certificate of amendment to incorporation; narrowed FY25 adjusted EBITDA guidance to $14M-$16M
• (November 2025) Reported Q3 2025 earnings beat with $1.65 EPS significantly above consensus
• (August 2025) Q2 2025 earnings showed 20% sequential sales growth in Rolvedon and 18.5% growth in Sympazan

Open the full interactive Assertio Holdings, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.